{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:56:07Z","timestamp":1747209367176,"version":"3.40.5"},"reference-count":0,"publisher":"National Library of Serbia","issue":"suppl. 1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Srp Arh Celok Lek","SRP ARH CELOK LEK","SRP ARK CELOK LEK","SRPSKI ARHIV CELOKUP"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>An immune-mediated, severe, acquired prothrombotic disorder, heparin-induced\n   thrombocytopenia type II (HIT II) occurs in 0.5-5% of patients exposed to\n   unfractionated heparin longer than 5-7 days. Arterial and venous thromboses\n   are induced by HIT II in about 35-50% of patients. Typical death rate for HIT\n   is about 29%, while 21% of HIT patients result in amputation of a limb. The\n   trend towards the occurrence of HIT due to the administration of low\n   molecular weight heparins (LMWH) taking ever conspicuous place in the\n   standard venous thromboembolism (VTE) prophylaxis has been more frequently\n   observed recently. It is considered that LMWH may cause HIT II in about\n   0.25-1%. The need for further modification of HIPA assays with LMWH has been\n   imposed in the HIT laboratory diagnostics, heretofore overburdened with\n   complexity. There are several constantly opposing problems arising in HIT\n   laboratory diagnostics, one of which is that in a certain number of patients\n   immunologic assays detect nonpathogenic antibodies (mainly IgM or IgA\n   heparin-PF4 antibodies) while, on the other hand, the occurrence of HIT\n   pathogenetically mediated by minor antigens (neutrophil-activating peptide 2\n   or interleukin 8) may be neglected in certain cases. The following factors\n   play an important role in the interpretation of each laboratory HIT assays\n   performed: 1. correlation with HIT clinical probability test, the best known\n   of which is 4T?score, 2. the interpretation of the laboratory findings\n   dependent on the time of the thrombocytopenia onset, as well as 3. the\n   sensitivity and specificity of each test respectively. The HIT diagnostics in\n   the presence of other comorbid states which may also induce thrombocytopenia,\n   more precisely known as pseudo HIT (cancer, sepsis, disseminated\n   intravascular coagulation, pulmonary embolism, antiphospholipid syndrome,\n   etc), represents a specific clinical problem.<\/jats:p>","DOI":"10.2298\/sarh10s1069a","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T12:52:43Z","timestamp":1437569563000},"page":"69-73","source":"Crossref","is-referenced-by-count":4,"title":["Obstacles in the diagnostics and therapy of heparin-induced thrombocytopenia"],"prefix":"10.2298","volume":"138","author":[{"suffix":"M.","given":"Nebojsa","family":"Antonijevic","sequence":"first","affiliation":[{"name":"Clinical Centre of Serbia, Institute of Cardiovascular Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nebojsa","family":"Radovanovic","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia, Institute of Cardiovascular Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodan","family":"Obradovic","sequence":"additional","affiliation":[{"name":"Military Medical Academy, Clinic of Emergency Medicine, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-184X","authenticated-orcid":false,"given":"Dragica","family":"Vucelic","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia, Institute of Digestive Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojan","family":"Stojanovic","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia, Institute of Cardiovascular Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijela","family":"Mikovic","sequence":"additional","affiliation":[{"name":"Blood Transfusion Institute of Serbia, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Kovac","sequence":"additional","affiliation":[{"name":"Blood Transfusion Institute of Serbia, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Kocica","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia, Institute of Cardiovascular Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Tadic","sequence":"additional","affiliation":[{"name":"Blood Transfusion Institute of Serbia, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Antonijevic","sequence":"additional","affiliation":[{"name":"Blood Transfusion Institute of Serbia, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snezana","family":"Draskovic","sequence":"additional","affiliation":[{"name":"Blood Transfusion Institute of Serbia, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Djordjevic","sequence":"additional","affiliation":[{"name":"Institute of Molecular Genetics and Genetic Engineering, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branko","family":"Calija","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases \u201cDedinje\u201d, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan","family":"Perunicic","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia, Institute of Cardiovascular Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zorana","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia, Institute of Cardiovascular Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1078","container-title":["Srpski arhiv za celokupno lekarstvo"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T10:29:03Z","timestamp":1685356143000},"score":1,"resource":{"primary":{"URL":"https:\/\/doiserbia.nb.rs\/Article.aspx?ID=0370-817910069A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":0,"journal-issue":{"issue":"suppl. 1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2298\/sarh10s1069a","relation":{},"ISSN":["0370-8179","2406-0895"],"issn-type":[{"type":"print","value":"0370-8179"},{"type":"electronic","value":"2406-0895"}],"subject":[],"published":{"date-parts":[[2010]]}}}